The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Sernbo, Sandra ^a   Gustavsson, Elin ^a   Brennan, Donal J ^b   Gallagher, William M ^b   Rexhepaj, Elton ^b   Rydnert, Frida ^a   Jirström, Karin ^c   Borrebaeck, Carl A K ^a   Ek, Sara ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA methylation; EOC; Epigenetic regulation; SOX11

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; TRANSCRIPTION FACTOR SOX11; SOX11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DNA METHYLATION; EPITHELIAL OVARIAN CANCER; FEMALE; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PROMOTER METHYLATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SOXC TRANSCRIPTION FACTORS;

EID: 80053173700     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-405     Document Type: Article

References (41)

1. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human pathology 2008, 39:1239-1251. 10.1016/j.humpath.2008.01.003, 18602670.
2. Silverberg SG. Prognostic significance of pathologic features of ovarian carcinoma. Current topics in pathology 1989, 78:85-109.
3. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010, 20:945-952. 10.1111/IGC.0b013e3181dd0110, 20683400.
4. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009, 15:2448-2455. 10.1158/1078-0432.CCR-08-2430, 3050629, 19318476.
5. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS medicine 2008, 5:e232. 10.1371/journal.pmed.0050232, 2592352, 19053170.
6. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. British journal of cancer 2006, 94:1369-1374. 10.1038/sj.bjc.6603116, 2361284, 16641903.
7. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007, 25:2873-2883. 10.1200/JCO.2007.11.0932, 17617518.
8. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009, 374:1371-1382. 10.1016/S0140-6736(09)61338-6, 19793610.
9. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer research 2002, 62:4722-4729.
10. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11:6422-6430. 10.1158/1078-0432.CCR-05-0508, 16166416.
11. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008, 14:5198-5208. 10.1158/1078-0432.CCR-08-0196, 18698038.
12. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010, 23:105-112. 10.1038/modpathol.2009.140, 19801969.
13. Dictor M, Ek S, Sundberg M, Warenholt J, Gyorgy C, Sernbo S, Gustavsson E, Abu-Alsoud W, Wadstrom T, Borrebaeck C. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 2009, 94:1563-1568. 10.3324/haematol.2009.008474, 2770967, 19880779.
14. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008, 111:800-805. 10.1182/blood-2007-06-093401, 17934069.
15. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, Camacho F, Bea S, Hartmann E, Amador V, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer research 2010, 70:1408-1418. 10.1158/0008-5472.CAN-09-3419, 20124476.
16. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009, 94:1555-1562. 10.3324/haematol.2009.010264, 2770966, 19880778.
17. Wang X, Asplund AC, Porwit A, Flygare J, Smith CI, Christensson B, Sander B. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. British journal of haematology 2008, 143:248-252. 10.1111/j.1365-2141.2008.07329.x, 18729857.
18. Gustavsson E, Sernbo S, Andersson E, Brennan DJ, Dictor M, Jerkeman M, Borrebaeck CA, Ek S. SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Molecular cancer 2010, 9:187. 10.1186/1476-4598-9-187, 2913986, 20624318.
19. Brennan DJ, Ek S, Doyle E, Drew T, Foley M, Flannelly G, O'Connor DP, Gallagher WM, Kilpinen S, Kallioniemi OP, et al. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur J Cancer 2009, 45:1510-1517. 10.1016/j.ejca.2009.01.028, 19272768.
20. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. Journal of internal medicine 1993, 233:45-51. 10.1111/j.1365-2796.1993.tb00647.x, 8429286.
21. Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, Nilsson JA, Stavenow L. Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. Journal of internal medicine 1996, 239:489-497. 10.1046/j.1365-2796.1996.483819000.x, 8656142.
22. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. Journal of translational medicine 2010, 8:78. 10.1186/1479-5876-8-78, 2936876, 20727170.
23. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008, 10:R89. 10.1186/bcr2187, 2614526, 18947395.
24. Manning AP, Mes-Masson AM, Seymour RJ, Tetrault M, Provencher DM, Tonin PN. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. Molecular carcinogenesis 1999, 24:218-225. 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A, 10204806.
25. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer research 1983, 43:5379-5389.
26. Lau DH, Ross KL, Sikic BI. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. Cancer research 1990, 50:4056-4060.
27. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004, 10:1032-1042. 10.1016/j.ymthe.2004.08.013, 15564135.
28. Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirstrom K. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 2010, 3:14. 10.1186/1757-2215-3-14, 2902477, 20565760.
29. Gomez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecologic oncology 2010, 118:88-92. 10.1016/j.ygyno.2010.03.012, 20439111.
30. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73:1859-1864. 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L, 8137211.
31. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008, 26:995-1005. 10.1200/JCO.2006.07.9970, 18195328.
32. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95. 10.1046/j.1365-2559.2001.01042.x, 11207821.
33. Larson BL, Ylostalo J, Lee RH, Gregory C, Prockop DJ. Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue engineering 2010, 16:3385-3394. 10.1089/ten.tea.2010.0085, 20626275.
34. Kurman RJ, McConnell TG. Precursors of endometrial and ovarian carcinoma. Virchows Arch 2010, 456:1-12. 10.1007/s00428-009-0824-9, 19859732.
35. Conrotto P, Andreasson U, Kuci V, Borrebaeck CA, Ek S. Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo. Mol Oncol 2011,
36. Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu JC, Yan PS, Huang TH. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer research 2003, 63:6110-6115.
37. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer research 1998, 58:95-101.
38. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21:5483-5495. 10.1038/sj.onc.1205699, 12154409.
39. Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B, Martin-Guerrero I, Agirre X, Lujambio A, Richter J, Xargay-Torrent S, et al. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS One 2011, 6:e21382. 10.1371/journal.pone.0021382, 3124503, 21738649.
40. Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecologic oncology 2010, 116:195-201. 10.1016/j.ygyno.2009.09.043, 2813995, 19854495.
41. Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Critical reviews in oncology/hematology 2009, 69:12-27. 10.1016/j.critrevonc.2008.05.001, 18595727.